

[Click here to view linked References](#)

1 SHORT COMMUNICATION

2 ***Fasciola hepatica* calcium binding protein FhCaBP2: Structure of the**
3
4
5 **dynein light chain-like domain**

6
7
8
9
10 **Thanh H. Nguyen^{1,2}, Charlotte M. Thomas^{3,4}, David J. Timson^{3,5} and Mark J. van Raaij¹**

11
12 ¹Dpto de Estructura de Macromoleculas, Centro Nacional de Biotecnologia - CSIC, calle Darwin 3, E-28049
13
14 Madrid, Spain.

15
16 ²Genetic Engineering Laboratory, Institute of Biotechnology (IBT-VAST), 18 Hoang Quoc Viet, Cau Giay,
17
18 Hanoi, Vietnam.

19
20 ³School of Biological Sciences, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast,
21
22 BT9 7BL, UK.

23
24 ⁴Institute for Global Food Security, Queen's University Belfast, 18-30 Malone Road, Belfast, BT9 5BN, UK.

25
26 ⁵School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road
27
28 Brighton BN2 4GJ, UK.

29
30
31
32 Running title: FhCaBP2 structure
33
34
35

36 **Acknowledgements** Crystallographic data was collected at beamline XALOC-BL13 at ALBA
37
38 Synchrotron Light Facility with the collaboration of Fernando Gil and Jordi Juanhuix. MJvR thanks the Spanish
39
40 Ministry of Economy and Competitiveness for grants BFU2011-24843 and BFU2014-53425-P. THN received a
41
42 PhD fellowship from the Consejo Superior de Investigaciones Científicas and Vietnam Academy of Science and
43
44 Technology. CMT is in receipt of a PhD studentship from the Department of Employment and Learning,
45
46 Northern Ireland (DELNI, UK).
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

25 **Abstract** The common liver fluke *Fasciola hepatica* causes an increasing burden on human and animal
1 health, partly because of the spread of drug resistant isolates. As a consequence there is considerable interest in
2 developing new drugs to combat liver fluke infections. A group of potential targets is a family of calcium
3 binding proteins which combine an N-terminal domain with two EF-hand motifs and a C-terminal domain with
4 predicted similarity to dynein light chains (DLC-like domain). The function of these proteins is unknown,
5 although in several species they have been localised to the tegument, an important structure at the host-parasite
6 interface. Here, we report the x-ray crystal structure of the DLC-like domain of FhCaBP2 (*Fasciola hepatica*
7 **calcium binding protein 2**), solved using single-wavelength anomalous diffraction and refined at 2.3 Å
8 resolution in two different crystal forms. The FhCaBP2 DLC-like domain has a structure similar to other DLC
9 domains, with an anti-parallel β-sheet packed against an α-helical hairpin. Like other DLC domains, it dimerizes
10 through its β₂-strand, which extends in an arch and forms the fifth strand in an extended β-sheet of the other
11 monomer. The structure provides molecular details of the dimerization of FhCaBP2, **the first example from this**
12 **family of parasite proteins.**
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Keywords** Liver fluke · Calcium-Binding Protein · Dynein Light Chain · Crystal Structure · Helminth
29 Protein
30
31
32
33
34
35
36
37
38
39
40
41

42 Introduction

43 Parasitic infections from worms of the class Trematoda are causing an increasing burden on human and animal
44 health. For example, it is estimated that several million humans are infected with the common liver fluke
45 *Fasciola hepatica* – and this zoonotic infection is classed by WHO as a neglected tropical disease (Robinson
46 and Dalton 2009). Globally, the impact of *F. hepatica* infections of farm animals is estimated to result in several
47 billions of dollars of agricultural losses per annum (Boray 1994; Schweizer et al. 2005). This increasing burden
48 results partly because of the spread of drug resistant isolates of liver flukes. Resistance to triclabendazole, a
49 generally safe and effective treatment for liver fluke infections, is now widespread in flukes which infect farm
50 animals and the first incidences of humans infected with resistant flukes has also been reported (Cabada et al.
51 2016; Gil et al. 2014; Winkelhagen et al. 2012). As a consequence, there is considerable interest in developing
52 new drugs to combat liver fluke, and other trematode, infections. Much of this interest focuses on the
53 identification of possible novel targets from these organisms. Proteins which are unique to trematodes, and not
54 present in the host, are particularly attractive, since antagonism of these molecules is less likely to have
55 detrimental effects on the host.

56 One such group of potential targets is a family of calcium binding proteins which combine an N-
57 terminal domain with two EF-hand motifs and a C-terminal domain with predicted similarity to dynein light
58 chains (DLC-like domain) (Russell and Timson 2014; Thomas and Timson 2016). **This combination of domains
59 is unique: no mammalian proteins with EF-hand and DLC-like domains in the same protein are known.** The
60 function of these proteins is unknown, **and it is not known if the proteins are essential for infection or survival of
61 the parasite (knock-out or RNAi studies on these proteins have not been reported).** One family member
62 (SmTAL3/Sm20.8 from *Schistosoma mansoni*) has been shown to form part of a high molecular mass protein
63 complex together with dynein light chain; therefore, it has been postulated that its role may be to link calcium
64 signalling with microtubule regulation (Hoffmann and Strand 1997). However, it should be noted that SmTAL3
65 does not bind calcium ions, although other family members do (Thomas et al. 2015). In several species the
66 family members have been localised to the tegument, suggesting a potential role in the regulation of this
67 important structure at the host-parasite interface (Havercroft et al. 1990; Huang et al. 2007; Jeffs et al. 1991;
68 Kim et al. 2012; Mohamed et al. 1998; Subpipattana et al. 2012; Vichasri-Grams et al. 2006; Xu et al. 2014;
69 Zhang et al. 2012). In *Schistosoma spp.*, there are typically large numbers of different family members
70 expressed. For example, *S. mansoni* has at least 13 different members and several of these have been shown to
71 illicit allergen-like IgE immune responses (Fitzsimmons et al. 2012). Consequently, these proteins are also

72 considered as possible vaccines as well as drug targets (Fitzsimmons et al. 2007; Fitzsimmons et al. 2004;
1
2 73 Zhang et al. 2012). In *F. hepatica*, there are at least four family members (FH22, FhCaBP2, FhCaBP3 and
3
4 74 FhCaBP4), with distinct biochemical properties (Banford et al. 2013; Orr et al. 2012; Ruiz de Eguino et al.
5
6 75 1999; Thomas and Timson 2015). Similarly, the *S. mansoni* tegumental allergen (TAL) proteins that have been
7
8 76 characterised biochemically show different drug and ion binding properties (Thomas et al. 2015). This suggests
9
10 77 that each protein may have a subtly different function in the organism (Russell and Timson 2014; Thomas and
11
12 78 Timson 2016).

13
14 79 A major barrier in understanding the biology of these proteins and in their possible development as
15
16 80 vaccines or as drug targets is a lack of experimental, high-resolution structural data. To date, a number of
17
18 81 molecular models have been reported but, like all models, these are highly reliant on the template structures
19
20 82 (Banford et al. 2013; Orr et al. 2012; Thomas et al. 2015; Thomas and Timson 2015). Crystallization, but not
21
22 83 structure solution, of the DLC-like domain of *S. mansoni* TAL2 (SmTAL2, Sm21.7) has also been reported
23
24 84 (Costa et al. 2014). Here, we report the **crystallographic** structure of the DLC-like domain of FhCaBP2
25
26 85 (UniProt: A0A0B5GUS3).

27 28 86 29 30 87 **Materials and Methods**

31 32 88 **Purification and crystallisation of FhCaBP2**

33
34 89 Recombinant hexahistidine-tagged FhCaBP2 was expressed in *Escherichia coli* HMS174(DE3) and initial
35
36 90 purification carried out using cobalt affinity resin as previously described (Thomas and Timson 2015). Further
37
38 91 purification was conducted by anion-exchange chromatography (Resource Q6 column, GE-Healthcare
39
40 92 Biosciences, Uppsala, Sweden), after dialysing the protein against 10 mM Tris-HCl pH 8.5, 1 mM dithiothreitol.
41
42 93 The protein was eluted in the same buffer with a linear gradient of 0-0.65 M sodium chloride, and eluted in two
43
44 94 adjacent peaks around 0.3 M. It is not clear what the difference is between the two peaks, because on SDS-
45
46 95 PAGE the same band is observed. Fractions containing pure protein from each peak were pooled separately and
47
48 96 concentrated up to 16 mg/ml using an Amicon Ultra concentrator with a molecular weight cut-off of 10 kDa
49
50 97 (Millipore, Billerica MA, USA). Three washes with 10 ml of 10 mM Tris-HCl pH 8.5, 50 mM sodium chloride
51
52 98 were applied. The samples were stored at 4 °C prior to crystallization trials.

53
54 99 FhCaBP2 protein was crystallized using the sitting drop vapour diffusion method (MRC 2-well Swissci
55
56 100 crystallization plates, Molecular Dimensions, Newmarket, UK), adding 50 µl of precipitant solution to the
57
58 101 reservoir wells. To form the drops, protein solution (0.2 µl) was mixed with 0.2 µl of the respective reservoir
59
60
61
62
63
64
65

102 solution (Genesis RSP 150 workstation; Tecan, Männedorf, Switzerland). Plates were incubated at 21 °C. After
1 two months of incubation, a crystal was obtained in each of two drops, one in the presence of 20 % (w/v) PEG
2 103 3350 and 0.2 M sodium tartrate and one with the same precipitant and 0.2 M potassium citrate. To generate the
3 104 heavy atom derivative crystal, a few grains of solid methylmercury chloride were added to the reservoir of a
4 105 crystal grown in the presence of sodium tartrate. The drop was equilibrated overnight with the reservoir and 2 µl
5 106 of reservoir solution were then added to the drop and incubated for about 5 min. The native crystal and
6 107 derivative crystal were harvested with a Litholoop (Molecular Dimensions, Newmarket, UK) and flash-cooled
7 108 in liquid nitrogen without cryo-protection.
8 109

16 110 Six-histidine-tagged recombinant C-terminal domain (residues 99-189) was also expressed in *E. coli* as
17 111 previously described (Thomas and Timson 2015). It was purified using the same protocol as described above for
18 112 the full-length protein, in this case a single peak was observed after anion exchange chromatography, eluting at
19 113 around 0.15 M sodium chloride. Crystallization of C-terminal domain protein was performed in the same
20 114 manner as for the full-length protein, crystals were obtained within two weeks from the condition containing 20
21 115 % (w/v) PEG 3350 and 0.2 M sodium tartrate. Crystals were harvested as above.
22 116

30 117 **X-ray crystallography data collection and structure solution**

32 118 Crystallographic data were collected from a methylmercury chloride derivative crystal at the BL13-XALOC
33 119 beamline of the ALBA synchrotron (Juanhuix et al. 2014), using a wavelength at which significant anomalous
34 120 signal from the added mercury atoms was expected (1.0056 Å). Crystallographic data were integrated using
35 121 MOSFLM (Battye et al. 2011) and further processed using POINTLESS, SCALA and TRUNCATE (Evans
36 122 2011) from the CCP4-suite (Winn et al. 2011) to obtain structure factor amplitudes. Structure solution was done
37 123 using AUTOSHARP (Vonrhein et al. 2007), which employs SHELX for heavy atom substructure determination
38 124 (Sheldrick 2010), SHARP for phase determination (de La Fortelle and Bricogne 1997), SOLOMON for solvent
39 125 flattening (Abrahams and Leslie 1996) and ARPWARP for automated model building (Langer et al. 2008). The
40 126 auto-traced model was completed using COOT (Emsley et al. 2010) and refined using REFMAC5 (Murshudov
41 127 et al. 2011) (10% of reflections were selected for calculation of R_{free} (Brunger 1993)). For structure solution of
42 128 the non-derivatised C-terminal domain, data was also collected at BL13-XALOC. Structure solution by
43 129 molecular replacement was performed using PHASER (McCoy et al. 2007), after increasing the number of
44 130 allowed C-α clashes to 20%. The model was completed using COOT and refined using REFMAC5 as before.
45 131 Validation was done with MOLPROBITY (Chen et al. 2010). Structure comparisons, including r.m.s.d. and Z-

score calculations, were performed using the DALI server (Holm and Rosenstrom 2010). Figures were made using PyMol (The PyMol Molecular Graphics System, Version 1.5.0.4. Schrödinger, LLC). Protein assembly parameters were calculated using PISA (Krissinel and Henrick 2007) and the PIC server (Tina et al. 2007). Data collection, phasing and refinement parameters are shown in Table 1.

Results and Discussion

Structure of the DLC-like domain of FhCaBP2

In initial experiments, we attempted to crystallise full length FhCaBP2 (residues 1-189). This resulted in the formation of single prism-shaped crystals (Figure 1A), belonging to space group $P4_12_12$, with one protein molecule in the asymmetric unit. However, upon analysis, it became apparent that these crystals only contained the C-terminal DLC-like domain of the protein. Interestingly, a similar outcome was reported following attempts to crystallise SmTAL2 (Costa et al. 2014). This suggests that the flexible linker between the EF-hand domain and the DLC-like domain in these proteins is susceptible to degradation by proteases. Indeed, we speculate that this may be important in their normal, *in vivo* functioning. The complete absence of the EF-hand domain in the structure is interesting and may indicate that this domain is less stable to proteolysis than the DLC-like domain. Later, we also crystallized the C-terminal domain (residues 99-189) separately. In this case, crystals belonging to space group $P6_422$ were obtained, also with one protein monomer in the asymmetric unit (Figure 1B).

A methylmercury chloride derivative of a crystal of the $P4_12_12$ form was prepared and diffraction data were collected from it (Table 1). Three heavy atom sites were located, of which one was well-occupied and later modelled as a mercury ion between cysteine residues 153 and 181. Single-wavelength anomalous dispersion led to good phases, which were used in an automatic model building procedure to yield a protein model with 97 residues (Ala92 to Arg188; the entire C-terminal DLC-like domain plus a few residues of the linker between the N-terminal EF-hand domain and C-terminal DLC-like domain). Careful refinement at 2.3 Å resolution and inspection of electron density maps allowed the addition of a mercury ion, two chloride ions and 57 water molecules (PDB code 5FWZ). Using this structure, the structure of a native crystal of the $P6_422$ space group was solved by molecular replacement and refined to 2.3 Å resolution. The final model of this structure contains 89 amino acids, Ile99 to Pro187, plus nine residues of the N-terminal expression tag and eight water molecules (PDB code 5FX0). The packing of the molecules in the two crystal forms is very different, apart from the dimer interaction described below. The two structures of the DLC-domain are identical in the two crystal forms; a root

162 mean squared deviation (r.m.s.d) of only 0.5 Å is obtained when the C- α atoms of residues 99-187 are
163 superposed.

164 The structure of the DLC-like domain revealed a compact, largely β -sheet structure (Figure 2). It
165 consists of an anti-parallel β -sheet packed against a hairpin of α -helices (Figure 2A). The order of the β -strands
166 is $\beta_0\beta_3\beta_4\beta_1$ and the $\alpha_1\alpha_2$ hairpin is between strands β_0 and β_1 in the primary sequence. The structure is similar to
167 many of the DLC domains in the PDB database. They can be superimposed with an r.m.s.d. of 1.5-2.0 Å (81-85
168 superposed residues, DALI Z-scores between 13 and 14). Although Cys153 and Cys181 are physically close to
169 each other, no cystine bond is observed between them. Cystine bonds are also not observed in other DLC-like
170 domains (for example in PDB entries 1CMI, 3E2B or 4DS1 (Benison et al. 2008; Liang et al. 1999; Romes et al.
171 2012)). Two *cis*-peptides are observed in the structure, Ala92-Pro93 (in the putative linker between the N- and
172 C-terminal domains) and Arg149-Val150, a non-proline *cis*-peptide. Non-proline *cis*-peptides are rare, but the
173 observed electron density clearly indicates their presence in this case. The experimental structure is in good
174 agreement with the DLC-like domain of the previously published molecular model (Thomas and Timson 2015);
175 residues 99-187 can be superposed with an rmsd of 2.7 Å (Figure 3A). Significant differences are only observed
176 for the inter-domain linker, the loop between α_1 and α_2 , strand β_2 and the very C-terminal residues. The model
177 was of a monomeric protein and so this structure enables us to understand, for the first time, the molecular basis
178 of dimerization in these proteins.

179

180 **Dimer interactions**

181 The DLC-like domain of FhCaBP2 dimerises through an extended β -sheet structure (Figure 2). The interface is
182 largely composed of the β_2 -strand from each subunit, bent through almost 180° into an arch. Strand β_2 protrudes
183 from the back of the molecule and interacts with strand β_1 of another monomer to form a symmetric dimer (i.e.,
184 the dimer contains β -sheets $\beta_0\beta_3\beta_4\beta_1\beta_2'$ and $\beta_0'\beta_3'\beta_4'\beta_1'\beta_2$; Figure 2B). In both crystal forms, the same
185 crystallographic dimer is observed, with an inter-monomer interface of about 1100 Å² and an estimated
186 dissociation energy of approximately 15 kcal.mol⁻¹. Key residues in the interaction are those belonging to the β_1 -
187 and β_2 -strands, five main-chain hydrogen bonds hold together each of the extended β -sheets. Side-chains of
188 residues of the same strands also contribute to the hydrophobic interaction interface. Further hydrophobic
189 interactions are formed between residues of the β_2 -strand and the α_2 -helix and between opposing β_1 - and β_4 -
190 strands. At least six additional hydrogen bonds involving side-chains are also present. **Homo-dimer formation of**
191 **the FhCaBP2 DLC-like domain is consistent with biochemical data (Thomas and Timson 2015) and identical to**

192 known structures of DLC-like domains. This arrangement is also seen in DLC dimers from *Saccharomyces*
193 *cerevisiae* (Dyn2p) (PDB 4DS1, Z-score 13.8, r.m.s.d. 1.8 Å² when 84 Cα atoms are aligned; Romes et al.
194 2012), in the rat 8 kDa DLC (PDB 1F3C; Z-score 10.3, r.m.s.d. 2.2 Å² when 86 Cα atoms are aligned; Fan et al.
195 2001) and in human dynein light chain 8 (PDB 3ZKE, Z-score 13.9, r.m.s.d. 1.6 Å² when 83 Cα atoms are
196 aligned; Gallego et al. 2013), albeit with somewhat smaller interaction surfaces (around 800 Å²) and predicted
197 interaction energies (around 10 kcal.mol⁻¹). While the conservation of the structural scaffold means that dimer
198 interactions are almost identical in terms of main-chain hydrogen bonds, the low sequence identity between the
199 FhCaBP2 DLC-like domain with the DLC domains mentioned above of around 20% means side-chain
200 electrostatic interactions, hydrogen bonds and van der Waals interactions are very different.

201 In *S. cerevisiae* Dyn2p, peptides from the nuclear pore component Nup159p dock into the cleft
202 between the two monomers of the DLC, further extending the β-sheet structure (Romes et al. 2012). Peptides
203 from neuronal nitric oxide synthase (nNOS) and BCL2-like 11 (BIM, an apoptosis regulator) both bind into the
204 cleft between the monomers in a similar arrangement to the Dyn2p-Nup159p interaction (PDB 1F95, 1F96 (Fan
205 et al. 2001)). In human dynein light chain 8, peptides from the Nek7 protein kinase also bind to the same site
206 (PDB 3ZKE, 3ZKF; Gallego et al. 2013). This demonstrates that a wide variety of different binding partners can
207 interact with DLC dimers in this manner and suggests that FhCaBP2 (and other proteins from this family) may
208 also exploit this mode of protein-protein interaction. A superposition of the FhCaBP2 DLC-like domain with the
209 human dynein light chain 8 - Nek7 protein kinase peptide structure (Figure 3B) shows that, although the
210 structures generally overlap very well, the α₁α₂-loop, β₁β₂-loop, β₂-strand and β₂β₃-loop adopt somewhat
211 different conformations (in *S. cerevisiae* Dyn2p and rat 8 kDa DLC, these secondary structure elements have a
212 very similar conformation to that in human dynein light chain 8). In the superposition, the FhCaBP2 β₂β₃-loop
213 (highlighted with an arrow in Figure 3B) overlaps with the peptide, suggesting that the FhCaBP2 DLC-like
214 domain, if it is involved in further protein-protein interactions, may need to change conformation to bind
215 another protein or may bind its interaction partners in a somewhat different manner.

217 Conclusions

218 The structure reported here enables us to understand the dimerization of DLC-like domains of this class of
219 proteins and validates the modelling techniques used to predict the structure of this domain in a range of
220 proteins. It also suggests how this family of proteins might interact with other proteins through the DLC-like
221 domain. The *in vivo* functions of this family of proteins remain enigmatic. However, it is hypothesised that they

222 may perform roles in calcium signalling in the tegument (Thomas and Timson 2016). If such a role is
1
2 223 demonstrated then they would be very attractive targets for the development of novel anthelmintic drugs. One
3
4 224 possible strategy would be the identification of molecules which disrupt dimer formation. This structure
5
6 225 provides vital information to enable that process and the low sequence similarity in the dimerization region
7
8 226 suggests that it should be possible to identify molecules which selectively target trematode proteins without
9
10 227 affecting host DLCs.

11
12 228

13 14 229 **References**

- 15
16
17 230 Abrahams JP, Leslie AG (1996) Methods used in the structure determination of bovine mitochondrial F1
18 231 ATPase. *Acta Crystallogr D Biol Crystallogr* 52(Pt 1):30-42 doi:10.1107/s0907444995008754
19 232 Banford S, Drysdale O, Hoey EM, Trudgett A, Timson DJ (2013) FhCaBP3: A *Fasciola hepatica* calcium
20 233 binding protein with EF-hand and dynein light chain domains. *Biochimie* 95:751-758
21 234 doi:10.1016/j.biochi.2012.10.027; 10.1016/j.biochi.2012.10.027
22 235 Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG (2011) iMOSFLM: a new graphical interface for
23 236 diffraction-image processing with MOSFLM. *Acta Crystallogr D Biol Crystallogr* 67(Pt 4):271-81
24 237 doi:10.1107/s0907444910048675
25 238 Benison G, Karplus PA, Barbar E (2008) The interplay of ligand binding and quaternary structure in the diverse
26 239 interactions of dynein light chain LC8. *J Mol Biol* 384(4):954-66 doi:10.1016/j.jmb.2008.09.083
27 240 Boray JC (1994) Diseases of domestic animals caused by flukes. Food and Agricultural Organisation of the
28 241 United Nations, Rome
29 242 Brunger AT (1993) Assessment of phase accuracy by cross validation: the free R value. Methods and
30 243 applications. *Acta Crystallogr D Biol Crystallogr* 49(Pt 1):24-36 doi:10.1107/s0907444992007352
31 244 Cabada MM, Lopez M, Cruz M, Delgado JR, Hill V, White AC, Jr. (2016) Treatment Failure after Multiple
32 245 Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series. *PLoS Negl*
33 246 *Trop Dis* 10(1):e0004361 doi:10.1371/journal.pntd.0004361
34 247 Chen VB, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta*
35 248 *Crystallogr D Biol Crystallogr* 66(Pt 1):12-21 doi:10.1107/s0907444909042073
36 249 Costa MA, Rodrigues FT, Chagas BC, Rezende CM, Goes AM, Nagem RA (2014) Preliminary crystallographic
37 250 studies of a *Schistosoma mansoni* antigen (Sm21.7) dynein light-chain (DLC) domain. *Acta Crystallogr*
38 251 *F, Struct Biol Commun* 70(Pt 6):803-807 doi:10.1107/S2053230X14009273
39 252 de La Fortelle E, Bricogne G (1997) Maximum-likelihood heavy-atom parameter refinement for multiple
40 253 isomorphous replacement and multiwavelength anomalous diffraction methods. *Methods in*
41 254 *Enzymology*. Volume 276. Academic Press, p 472-494
42 255 Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D*
43 256 *Biol Crystallogr* 66(Pt 4):486-501 doi:10.1107/s0907444910007493
44 257 Evans PR (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics.
45 258 *Acta Crystallogr D Biol Crystallogr* 67(Pt 4):282-92 doi:10.1107/s090744491003982x
46 259 Fan J, Zhang Q, Tochio H, Li M, Zhang M (2001) Structural basis of diverse sequence-dependent target
47 260 recognition by the 8 kDa dynein light chain. *J Mol Biol* 306(1):97-108 doi:10.1006/jmbi.2000.4374
48 261 Fitzsimmons CM, et al. (2012) The *Schistosoma mansoni* tegumental-allergen-like (TAL) protein family:
49 262 influence of developmental expression on human IgE responses. *PLoS Negl Trop Dis* 6(4):e1593
50 263 doi:10.1371/journal.pntd.0001593
51 264 Fitzsimmons CM, et al. (2007) Factors affecting human IgE and IgG responses to allergen-like *Schistosoma*
52 265 *mansoni* antigens: Molecular structure and patterns of in vivo exposure. *Int Arch Allergy Imm*
53 266 *142(1):40-50* doi:10.1159/000095997
54 267 Fitzsimmons CM, Stewart TJ, Hoffmann KF, Grogan JL, Yazdanbakhsh M, Dunne DW (2004) Human IgE
55 268 response to the *Schistosoma haematobium* 22.6 kDa antigen. *Parasite Immunol* 26(8-9):371-376
56 269 doi:10.1111/j.0141-9838.2004.00721.x
57 270 Gallego P, Velazquez-Campoy A, Regue L, Roig J, Reverter D (2013) Structural analysis of the regulation of
58 271 the DYNLL/LC8 binding to Nek9 by phosphorylation. *J Biol Chem* 288(17):12283-12294
59 272 doi:10.1074/jbc.M113.459149
60
61
62
63
64
65

273 Gil LC, Diaz A, Rueda C, Martinez C, Castillo D, Apt W (2014) [Resistant human fascioliasis: report of four
1 274 patients]. *Rev Med Chile* 142(10):1330-3 doi:10.4067/s0034-98872014001000014
2 275 Havercroft JC, Huggins MC, Dunne DW, Taylor DW (1990) Characterisation of Sm20, a 20-kilodalton
3 276 calcium-binding protein of *Schistosoma mansoni*. *Mol Biochem Parasitol* 38(2):211-219
4 277 Hoffmann KF, Strand M (1997) Molecular characterization of a 20.8-kDa *Schistosoma mansoni* antigen.
5 278 Sequence similarity to tegumental associated antigens and dynein light chains. *Journal Biol Chem*
6 279 272(23):14509-14515
7 280 Holm L, Rosenstrom P (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res* 38(Web Server
8 281 issue):W545-9 doi:10.1093/nar/gkq366
9 282 Huang Y, et al. (2007) A novel tegumental protein 31.8 kDa of *Clonorchis sinensis*: sequence analysis,
10 283 expression, and immunolocalization. *Parasitol Res* 102(1):77-81 doi:10.1007/s00436-007-0728-z
11 284 Jeffs SA, Hagan P, Allen R, Correa-Oliveira R, Smithers SR, Simpson AJ (1991) Molecular cloning and
12 285 characterisation of the 22-kilodalton adult *Schistosoma mansoni* antigen recognised by antibodies from
13 286 mice protectively vaccinated with isolated tegumental surface membranes. *Mol Biochem Parasitol*
14 287 46(1):159-167 doi:0166-6851(91)90209-O
15 288 Juanhuix J, et al. (2014) Developments in optics and performance at BL13-XALOC, the macromolecular
16 289 crystallography beamline at the ALBA synchrotron. *J Synchrotron Radiat* 21(Pt 4):679-89
17 290 doi:10.1107/s160057751400825x
18 291 Kim YJ, et al. (2012) Identification and characterization of a novel 21.6-kDa tegumental protein from
19 292 *Clonorchis sinensis*. *Parasitol Res* 110:2061-2066 doi:10.1007/s00436-011-2681-0
20 293 Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. *J Mol Biol*
21 294 372(3):774-97 doi:10.1016/j.jmb.2007.05.022
22 295 Langer G, Cohen SX, Lamzin VS, Perrakis A (2008) Automated macromolecular model building for X-ray
23 296 crystallography using ARP/wARP version 7. *Nat Protoc* 3(7):1171-9 doi:10.1038/nprot.2008.91
24 297 Liang J, Jaffrey SR, Guo W, Snyder SH, Clardy J (1999) Structure of the PIN/LC8 dimer with a bound peptide.
25 298 *Nat Struct Biol* 6(8):735-740 doi:10.1038/11501
26 299 McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic
27 300 software. *J Appl Crystallogr* 40(Pt 4):658-674 doi:10.1107/s0021889807021206
28 301 Mohamed MM, Shalaby KA, LoVerde PT, Karim AM (1998) Characterization of Sm20.8, a member of a
29 302 family of schistosome tegumental antigens. *Mol Biochem Parasitol* 96(1-2):15-25 doi:S0166-
30 303 6851(98)00088-7
31 304 Murshudov GN, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. *Acta*
32 305 *Crystallogr D Biol Crystallogr* 67(Pt 4):355-67 doi:10.1107/s0907444911001314
33 306 Orr R, et al. (2012) FhCaBP4: a *Fasciola hepatica* calcium-binding protein with EF-hand and dynein light chain
34 307 domains. *Parasitol Res* 111(4):1707-1713 doi:10.1007/s00436-012-3010-y
35 308 Robinson MW, Dalton JP (2009) Zoonotic helminth infections with particular emphasis on fasciolosis and other
36 309 trematodiasis. *Philos Trans R Soc B-Biol Sci* 364(1530):2763-2776 doi:10.1098/rstb.2009.0089
37 310 Romes EM, Tripathy A, Slep KC (2012) Structure of a yeast Dyn2-Nup159 complex and molecular basis for
38 311 dynein light chain-nuclear pore interaction. *J Biol Chem* 287(19):15862-73
39 312 doi:10.1074/jbc.M111.336172
40 313 Ruiz de Eguino AD, et al. (1999) Cloning and expression in *Escherichia coli* of a *Fasciola hepatica* gene
41 314 encoding a calcium-binding protein. *Mol Biochem Parasitol* 101(1-2):13-21
42 315 Russell SL, Timson DJ (2014) Calcium binding proteins in the liver fluke, *Fasciola hepatica*. *New*
43 316 *Developments in Calcium Signaling Research*. Nova Science Publishers, Inc, p 89-104
44 317 Schweizer G, Braun U, Deplazes P, Torgerson PR (2005) Estimating the financial losses due to bovine
45 318 fasciolosis in Switzerland. *The Veterinary Record* 157(7):188-193 doi:157/7/188
46 319 Sheldrick GM (2010) Experimental phasing with SHELXC/D/E: combining chain tracing with density
47 320 modification. *Acta Crystallogr D Biol Crystallogr* 66(Pt 4):479-85 doi:10.1107/s0907444909038360
48 321 Subpipattana P, Grams R, Vichasri-Grams S (2012) Analysis of a calcium-binding EF-hand protein family in
49 322 *Fasciola gigantica*. *Exp Parasitol* 130:364-373 doi:10.1016/j.exppara.2012.02.005
50 323 Thomas CM, Fitzsimmons CM, Dunne DW, Timson DJ (2015) Comparative biochemical analysis of three
51 324 members of the *Schistosoma mansoni* TAL family: Differences in ion and drug binding properties.
52 325 *Biochimie* 108:40-47 doi:10.1016/j.biochi.2014.10.015 [doi]
53 326 Thomas CM, Timson DJ (2015) FhCaBP2: a *Fasciola hepatica* calcium-binding protein with EF-hand and
54 327 dynein light chain domains. *Parasitology*:1375-1386 doi:S0031182015000736
55 328 Thomas CM, Timson DJ (2016) A mysterious family of calcium binding proteins from parasitic worms.
56 329 *Biochemical Society Transactions*. In press.
57 330 Tina KG, Bhadra R, Srinivasan N (2007) PIC: Protein Interactions Calculator. *Nucleic acids Res* 35(Web Server
58 331 issue):W473-6 doi:10.1093/nar/gkm423

- 332 Vichasri-Grams S, Subpipattana P, Sobhon P, Viyanant V, Grams R (2006) An analysis of the calcium-binding
 1 333 protein 1 of *Fasciola gigantica* with a comparison to its homologs in the phylum Platyhelminthes. Mol
 2 334 Biochem Parasitol 146(1):10-23 doi:S0166-6851(05)00308-7 [pii]; 10.1016/j.molbiopara.2005.10.012
 3 335 Vonrhein C, Blanc E, Roversi P, Bricogne G (2007) Automated structure solution with autoSHARP. Methods in
 4 336 Molecular Biology 364:215-30 doi:10.1385/1-59745-266-1:215
 5 337 Winkelhagen AJ, Mank T, de Vries PJ, Soetekouw R (2012) Apparent triclabendazole-resistant human *Fasciola*
 6 338 *hepatica* infection, the Netherlands. Emerg Infect Dis 18(6):1028-1029 doi:10.3201/eid1806.120302
 7 339 Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol
 8 340 Crystallogr 67(Pt 4):235-42 doi:10.1107/s0907444910045749
 9 341 Xu J, et al. (2014) *Schistosoma japonicum* tegumental protein 20.8, role in reproduction through its calcium
 10 342 binding ability. Parasitol Res 113(2):491-497 doi:10.1007/s00436-013-3678-7
 11 343 Zhang Z, Xu H, Gan W, Zeng S, Hu X (2012) *Schistosoma japonicum* calcium-binding tegumental protein
 12 344 SjTP22.4 immunization confers praziquantel schistosomulmicide and antifecundity effect in mice.
 13 345 Vaccine 30(34):5141-5150 doi:10.1016/j.vaccine.2012.05.056
 14
 15 346
 16

17 347 Figure legends

18
 19 348 **Fig. 1** Crystals of the dynein light chain-like domain of the *Fasciola hepatica* calcium-binding protein 2. **a**
 20 349 Crystal (about 0.2 x 0.15 x 0.1 mm) belonging to the $P4_12_12$ spacegroup. **b** Crystal (about 0.45 x 0.2 x 0.2 mm)
 21 350 belonging to the $P6_422$ spacegroup.
 22
 23
 24

25 351
 26
 27 352 **Fig. 2** Structure of the DLC-like domain of FhCaBP2. **a** Monomer structure. The protein chain is coloured
 28 353 from blue (N-terminus) to red (C-terminus) in a rainbow colour scheme. β -Strands and α -helices are labelled. **b**
 29 354 Dimer structure. One monomer is coloured as in the previous panel, the other in cyan. Black arrows indicate
 30 355 where peptide interactions take place in other DLC domains. **c** Topology diagram of the dimer. Monomers are
 31 356 coloured as in the previous panel.
 32
 33
 34
 35
 36
 37
 38
 39

40 358 **Fig. 3** Comparison of the FhCaBP2 DLC-like domain with the modelled structure of the whole protein and
 41 359 with other DLC domains. **a** Superposition of the crystallographically determined structure of the FhCaBP2
 42 360 DLC-like domain (in green) and the previously published model of the entire structure (in magenta). The
 43 361 predicted calcium ion is shown in grey and the termini of the DLC-like domain are indicated. **b** Superposition of
 44 362 the FhCaBP2 DLC-like domain (in green) and human dynein light chain 8 (PDB entry 3ZKE, in blue). The
 45 363 peptide bound to human dynein light chain 8 is shown in yellow and the $\beta_2\beta_3$ -loop is highlighted with an arrow.
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

Table 1 Crystallographic data collection, phase determination, solvent flattening and refinement statistics (all values in parenthesis are for the highest resolution bin).

| Data collection | Derivative | Native |
|---|--|----------------------------|
| Space group | <i>P</i> 4 ₁ 2 ₁ 2 | <i>P</i> 6 ₄ 22 |
| Unit cell dimensions (a, b, c) (Å) | 59.9, 59.9, 81.3 | 57.9, 57.9, 90.0 |
| Wavelength (Å) | 1.0056 | 1.0047 |
| Resolution (Å) | 23.0-2.30 (2.42-2.30) | 50.0-2.20 (2.32-2.20) |
| Observed reflections | 7026 (990) | 5253 (726) |
| Multiplicity | 9.6 (9.7) | 11.0 (11.7) |
| Completeness (%) | 99.9 (100.0) | 100.0 (100.0) |
| Rmerge (%) | 11.7 (47.4) | 5.7 (49.3) |
| $\langle I/\sigma(I) \rangle$ | 12.0 (4.5) | 22.7 (5.0) |
| Wilson B (Å ²) | 30.9 | 41.2 |
| CC1/2 | 0.997 (0.929) | 1.000 (0.969) |
| CCanom | 0.567 (0.015) | -0.129 (0.049) |
| Phase determination | | |
| Number of heavy atom sites (Hg) | 3 | - |
| Anomalous phasing power | 1.185 | - |
| Figure of merit (acentric / centric) | 0.315/0.137 | - |
| Solvent flattening (53.6% solvent) | | |
| Hand score (original / inverted) | 0.593 / 0.247 | - |
| Overall correlation on $ E ^2$ / contrast | 3.72 | - |
| Refinement | | |
| Resolution range (Å) | 23.0-2.30 (2.36-2.30) | 50.0-2.30 (2.36-2.30) |
| No. reflections used in refinement | 6289 (445) | 4093 (282) |
| No. reflections used for R-free | 702 (44) | 484 (34) |
| R-factor (%) | 19.1 (23.0) | 20.2 (29.6) |
| R-free (%) | 24.1 (26.3) | 27.5 (49.4) |
| Number of protein / Hg / Cl / solvent atoms | 802 / 1 / 2 / 57 | 816 / 0 / 0 / 7 |
| Average B protein / Hg / Cl / solvent atoms (Å ²) | 37.0 / 48.4 / 62.3 / 40.4 | 63.1 / - / - / 55.1 |
| Ramachandran plot (favoured / allowed) (%) | 99.0 / 100.0 | 97.9 / 100.0 |
| R.m.s. deviation of bonds (Å) and angles (°) | 0.012 / 1.5 | 0.011 / 1.5 |
| PDB code | 5FWZ | 5FX0 |





